



King's Research Portal

DOI:

[10.1017/S0033291716002014](https://doi.org/10.1017/S0033291716002014)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Lally, J., Ajnakina, O., Di Forti, M., Trotta, A., Demjaha, A., Kolliakou, A., ... Murray, R. M. (2016). Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. *Psychological Medicine*, 46(15), 3231-3240. <https://doi.org/10.1017/S0033291716002014>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

**Two distinct patterns of treatment resistance: Clinical predictors of treatment
resistance in first episode schizophrenia spectrum psychoses**

John Lally^{1,2,3*}, Olesya Ajnakina^{1*}, Marta Di Forti^{4,5}, Antonella Trotta¹, Arsime Demjaha¹,
Anna Kolliakou⁶, Valeria Mondelli^{5,6}, Tiago Reis Marques¹, Carmine Pariante^{5,6}, Paola
Dazzan^{1,5}, Sukhwinder S Shergil^{1,2,5}, Oliver Howes^{1,7}, Anthony S David^{1,5}, James H
MacCabe^{1,2}, Fiona Gaughran^{1,2#} Robin M Murray^{1,2#}

*Both are first named authors and should be acknowledged as such

Both are last named authors and should be acknowledged as such

¹Department of Psychosis Studies, Institute of Psychiatry, Psychology &
Neuroscience (IoPPN), King's College London, London, UK

²National Psychosis Service, South London and Maudsley NHS Foundation Trust, London,
UK.

³Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont Hospital,
Dublin, Ireland.

⁴MRC Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry,
Psychology & Neuroscience, King's College London, London, UK

⁵National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at
South London and Maudsley NHS Foundation Trust and King's College London, UK

⁶Department of Psychological Medicine, Institute of Psychiatry, Psychology and
Neuroscience, Kings College London, UK

⁷MRC Clinical Sciences Centre (Imperial Hammersmith Campus)

Acknowledgement: The study was funded by the UK National Institute of Health Research (NIHR) Specialist Biomedical Research Centre (BRC) for Mental Health, under its IMPACT Programme (Grant Reference Number RP-PG-0606-1049), the NIHR BRC for Mental Health at SLaM NHS Foundation, and the IoPPN, King's College London (KCL), the Psychiatry Research Trust.

Declaration of Interest

S.S.S is supported by a European Research Council Consolidator Award. O.H. has received investigator-led grants and/or served as a speaker/consultant for Eli Lilly, Roche, Leyden-Delta, Lundbeck, Servier and Janssen-Cilag (J&J). A.S.D. has received honoraria from Janssen and Roche Pharmaceuticals. FG has received honoraria for advisory work and lectures from Roche, BMS, Lundbeck, Otsuka and Sunovion, is a collaborator on a NHS Innovations project co-funded by Janssen and has a family member with professional links to Lilly and GSK, including share options. R.M.M. has received honoraria from Janssen, Astra-Zeneca, Lilly, BMS.

The other authors have no declaration of interest to make.

Abstract

Background. Clozapine remains the only evidence based antipsychotic for treatment resistant schizophrenia (TRS). The ability to predict which patients with their first onset of schizophrenia would subsequently meet criteria for treatment resistance (TR) could help to diminish the severe functional disability which may ensue if TR is not recognised and correctly treated.

Methods. This is a 5 year longitudinal assessment of clinical outcomes in a cohort of 246 first-episode schizophrenia spectrum patients recruited as part of the NIHR Genetics and Psychosis (GAP) study conducted in South London from 2005-2010. We examined the relationship between baseline demographic and clinical measures and the emergence of TR. TR status was determined from a review of electronic case records. We assessed for associations with early, and late onset TR, and non-TR, and differences between those TR patients treated with clozapine and those who were not.

Results. Seventy percent (n=56) of TR patients, and 23% of the total study population (n=246) were treatment resistant from illness onset. Those who met criteria TR during the first five years of illness were more likely to have an early age of first contact for psychosis (<20 years) (OR=2.49, 95%CI 1.25-4.94) compared to those with non-TR. The relationship between an early age of first contact (<20 years) and TR was significant in patients of Black ethnicity (OR=3.71 95%CI 1.44-9.56); and patients of male gender (OR=3.13 95%CI 1.35-7.23).

Conclusions. For the majority of the TR group, antipsychotic treatment resistance is present from illness onset, necessitating increased consideration for the earlier use of clozapine.

Key words. Schizophrenia; treatment-resistant; first-episode psychosis; clozapine; longitudinal

Introduction

Treatment resistant schizophrenia (TRS) is a major cause of disability and functional impairment and affects up to 30% of those diagnosed with schizophrenia (Meltzer, 1997). Clozapine is the only evidenced based effective medication for TRS. In the UK, it is recommended that clozapine be offered to people with schizophrenia whose illness has not responded adequately to treatment despite the sequential use of adequate doses of at least two different antipsychotic drugs (NICE., 2014). At present it is not possible to predict those who will not respond to first line antipsychotic treatments.

Early identification of patients who require clozapine has the potential to improve clinical outcomes and minimize the social and functional disability that results from prolonged psychosis (Lewis *et al.*, 2006, Stroup *et al.*, 2016, Wheeler *et al.*, 2009). Previous studies investigating risk factors for TR have utilised clozapine prescription rates as a proxy measure of TR ((Nielsen *et al.*, 2012b, Schneider *et al.*, 2015, Stroup *et al.*, 2014), however, given the underutilisation of clozapine in clinical practice, such studies do not measure all people with TR. Although, a few potential risk factors for treatment resistance (TR), such as poor premorbid functioning, living in less urban areas, comorbid personality disorder, longer duration of untreated psychosis (DUP), greater severity of negative symptoms, and a younger age of illness onset have been suggested (Frank *et al.*, 2015, Martin and Mowry, 2016, Meltzer, 1997, Ortiz *et al.*, 2013, Schennach *et al.*, 2012, Vanelle *et al.*, 1994, Wimberley *et al.*, 2016), the predictive value of specific clinical and demographic factors on treatment resistance in first episode schizophrenia has not yet been widely investigated (Lin *et al.*, 2008). Further, while there is a large literature investigating predictors of treatment response and remission from illness onset (Carbon and Correll, 2014, Menezes *et al.*, 2006), TR has not been examined longitudinally as an outcome measure in FEP.

Therefore in our study, using a quasi-prospective cohort design, we sought to identify clinical and demographic risk factors, noted at first contact for psychosis, which were predictive of TR as assessed at the end of the first five years of illness. We explored associations between TR and a number of risk predictors, including type and severity of symptoms, gender, age at first contact for psychosis, ethnicity, duration of untreated psychosis (DUP) and premorbid level of functioning. We looked for differential clinical and social factors between those who showed “early-resistant” TR (E-TR) (within six months of first onset of schizophrenia with no period of remission from illness onset) and those with “late-resistant” TR (L-TR). We further assessed for differences between those with E-TR and those who were not treatment resistant (non-TR), and those with L-TR and those who were non-TR. We additionally compared the TR patients treated with clozapine with those who met the criteria for the TR but had not received clozapine, in terms of sociodemographic and clinical characteristics at the time of first illness onset.

Methods

Sample ascertainment

Participants were recruited as part of the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) Genetics and Psychosis (GAP) study conducted in the urban centre of South London, UK. Further details of the study are available in Di Forti et al (Di Forti *et al.*, 2013). For the purpose of the present study, only FEP cases who met criteria for the following ICD10 diagnoses: F20.0, F25.0, F28.0, F29.0, (referred to as schizophrenia spectrum psychosis; there are no cases of schizotypal disorder included) (WHO, 1992) validated by administration of the Schedules for Clinical Assessment in Neuropsychiatry (WHO, 1994) were included at baseline. All cases had been admitted to psychiatric inpatient units or seen by community based mental health teams of the South London and Maudsley (SLaM) NHS Foundation Trust, London between December 2005 and October 2010. All recruited cases were aged 18-65 and were resident in the study catchment area. The study

exclusion criteria were evidence of 1) psychotic symptoms precipitated by an organic cause; 2) evidence of transient psychotic symptoms resulting from acute intoxication as defined by ICD-10; 3) moderate or severe learning disabilities as defined by ICD-10; or 4) head injury causing clinically significant loss of consciousness.

Ethics

The BRC-GAP study was granted ethical approval by the South London and Maudsley and Institute of Psychiatry Local Research Ethics Committee (reference number: 05/Q0706/158). All cases gave informed written consent after reading a detailed information sheet.

Data ascertainment at baseline

Sociodemographic characteristics. Information on sociodemographic characteristics was collated using the Medical Research Council (MRC) Socio-demographic Schedule modified version (Mallett *et al.*, 2002). Age at first contact with mental health services for psychosis was further categorised into four groups based on the results of interquartile analyses (18-20, 21-25, 26-30, and > 31 years). Ethnicity was self-ascribed using the 16 categories employed by the UK Census in 2001 (www.statistics.gov.uk/census 2001). A detailed assessment of lifetime patterns of cannabis use and alcohol intake was collated employing the Cannabis Experience Questionnaire modified version (Di Forti *et al.*, 2009).

Clinical assessments. The baseline diagnoses were made from face-to-face interviews and mental health records according to ICD-10 criteria (WHO, 1992) utilising the Operational Criteria Checklists (OPCRIT) (McGuffin *et al.*, 1991). The OPCRIT system consists of a 90-item checklist and uses computerised diagnostic algorithms based on published criteria to provide a diagnostic category for each subject employing a number of classification systems (McGuffin *et al.*, 1991). The degree of psychopathology at first presentation to mental health services was measured on the Positive and Negative Syndrome Scale (PANSS) (Kay *et al.*, 1987). Overall functional disability was assessed using the Global Assessment of Functioning (GAF). Duration of untreated psychosis (DUP) was defined as the difference between the date of onset of psychotic symptoms to the date of treatment with antipsychotic medications (Malla *et al.*, 2006, Singh *et al.*, 2005).

The Family Interview for Genetic Studies (FIGS; <https://www.nimhgenetics.org/interviews/figs>) and clinical records were used to obtain information about patients' family history of mental health problems. A family history of psychosis variable was derived following consensus diagnoses based on the available information and referred to the presence or absence of a current or past psychotic disorder in at least one first-degree relative.

Current IQ was estimated using Wechsler Adult Intelligence Scale, version III (WAIS-III)(Wechsler D, 1997) and pre-morbid IQ was estimated using the Wechsler Test of Adult Reading (WTAR) (Wechsler, 2001). Premorbid and current IQ estimates, and the difference in IQ estimate between the premorbid and current IQ were compared between the TR and non TR groups.

Tracing patients at follow up

Approximately five years after first contact for psychosis, a retrospective database search of clinical history was carried out using the Electronic Psychiatric Clinical Records (EPCRs) database in the South London and Maudsley NHS Foundation Trust (SLaM). The EPCRs are the primary clinical records system within the Trust. The EPCRs were searched from the time of the FEP for a follow up period of five years in order to complete the data extraction. All deaths and emigrations up to and including those that occurred during the final year of follow up were identified by a case-tracing procedure with the Office for National Statistics (ONS) for England and Wales and the General Register Office (GRO) for Scotland.

Data at follow up

At follow-up, extensive information was collated across clinical and social outcome domains, from clinical records using the WHO Life Chart Schedule (LCS) extended version(Sartorius *et al.*, 1996). The LCS is designed to provide retrospective assessments of the long-term course of schizophrenia. Detailed information was collated on medication history including the number of antipsychotic medications used prior to commencing clozapine, medication initiation/discontinuation dates, antipsychotic dose, medication adherence and the primary reason for changing or discontinuing each antipsychotic medication.

Definitions of treatment resistance (TR)

Patients were defined as having TR if they had been treated with clozapine at any point during the five year follow up period. We also defined cases as treatment resistant if during the follow up period they showed little or no symptomatic improvement to two consecutive treatments with antipsychotic medications of adequate dose and duration (at least 6 weeks), even though they were not commenced on clozapine (NICE., 2014). An adequate daily dose of antipsychotic medication was defined according to a daily dose of at least 400mg chlorpromazine equivalence (Leucht *et al.*, 2014). We only included as cases those patients, who failed to respond, and not those who were intolerant of antipsychotic medications or those who self-discontinued medication.

Those who met the criteria for TR were divided into two subgroups: 1) “early-resistant” treatment resistance (E-TR) were those cases who met criteria for TR and who did not experience a symptomatic remission from the time of the first presentation and 2) “late-resistant” treatment resistance (L-TR) were those cases who had experienced a response to antipsychotics and attained a symptomatic remission (of at least 6 months duration), but at a later stage failed to respond to the ongoing use of non-clozapine antipsychotics, meeting the criteria for TR.

Similar to earlier work conducted in the same geographical region (Morgan *et al.*, 2014, Revier *et al.*, 2015) , and in keeping with work from Andreasen *et al.*, (Andreasen *et al.*, 2005), using information extracted from clinical records, remission was defined as the absence of overt psychotic symptoms, including positive or and negative symptoms (operationalised as a score of 0 or 1 on rating scale 2 in the SCAN (WHO, 1994); 0=absence, 1= symptom occurred, but fleeting, 2=symptom definitely present, 3=symptom present more or less continuously) for 6 months or longer. This definition of remission was not dependent on the presence of non-psychotic symptoms (e.g., depressed mood), nor whether the patients were receiving treatment during remission.

Data Analysis

Comparisons between the groups were conducted using χ^2 tests or *Fisher's* exact test for categorical variables and *t*-test or Mann-Whitney *U* test for continuous variables. Penalised logistic regression (PLR) was used to analyse the relationship between the predictors for TR (Heinze and Schemper, 2002). To explore the moderating effects of gender and ethnicity in predicting the risk for TR, we examined whether there were significant interactions between these variables and the independent predictors of TR status at follow up. Confounding factors were identified through correlation analyses between the primary outcome (i.e. TR vs non-TR at five years) and a number of clinical and sociodemographic factors measured at baseline and during the follow up period. All variables with $p < 0.05$ were included in the final model as confounding factors. Consequently, we adjusted the PLR analyses for the following variables: age at first contact for psychosis; living arrangements, and employment status and alcohol/substance misuse during the follow up period. All analyses were conducted in STATA release 14 (STATA Corp LP, USA).

Results

Sample characteristics

At first onset of psychosis, the sample comprised 283 cases with a diagnosis of a schizophrenia spectrum psychosis (ICD-10 classification codes: F20.0, F25.0, F28.0, F29.0), with an average age of 27.7 (SD=8.6) years. Seventy three percent were admitted to hospital at the time of their first presentation with psychosis and at the time of study recruitment, with 27% recruited from community based mental health settings. There were no significant differences between those recruited from an inpatient setting and those from a community setting in mean total PANSS scores ($p=0.35$), and mean negative PANSS scores ($p=0.70$) between those recruited from an inpatient setting and those from a community setting. Inpatients had significantly increased mean positive PANSS scores compared to those recruited from community settings ($p=0.02$).

A flow chart depicting how the cases were traced and administrative outcomes is presented in **Figure 1**. Approximately 5 years ($\text{mean}_{\text{years}}=5.4$, $\text{SD}=2.5$; 1,310 persons years) after first contact for psychosis, 10 (3.5%) had emigrated, 4 (1.4%) had died, 2 (0.7%) were excluded on the basis of lack of sufficient information to trace these patients over time and 21 (7.4%) cases we were unable to contact. Those who died were significantly older (Supplementary Table 1).

Core analytic cohort

We successfully traced 246 (86.7%) of the original cohort. Of these, 67.5% were male and 60.0% were of Black ethnicity. There were 240 cases with sufficient treatment information over the follow up period to determine TR or non-TR status. Eighty one (33.7%) of the cases met our criteria for TR and 159 (66.3%) were non-TR. The other six (2.4% of the core analytic cohort) cases had not received an adequate trial of antipsychotic to allow it to be determined if criteria for TR, or for non-TR was met.

Comparisons in baseline sociodemographic and clinical characteristics between the TR group and non-TR group are presented in **Table 1**. The TR group had a significantly younger age at first contact for FEP ($\text{mean}_{\text{years}}=25.2$, $\text{SD}=6.4$) than the non-TR group ($\text{mean}_{\text{years}}=27.9$, $\text{SD}=8.3$) ($t_{(238)}=2.57$, $p=0.01$). The median length of DUP for the non-TR group was 4 weeks (IQR=1-17) which was not significantly different from the DUP in the TR group (median=4.5 weeks, IQR=1-26) (U test=-0.92, $p=0.36$). Patients with TR did not have an increased family history of psychosis compared to patients in the non-TR group ($\chi^2=0.10$, $\text{df}=1$, $p=0.75$). There was no significant difference between the mean IQ in the TR group (mean=92.6 $\text{SD}=13.0$) compared with the non-TR group (mean= 87.5 $\text{SD}=16.2$) (Mann Whitney U test=-1.25 $p=0.22$). The mean premorbid IQ was higher in the TR group (mean=92.8 $\text{SD}=9.6$) compared to those in the non-TR group (mean=88.5 $\text{SD}=11.0$), but this did not reach statistical significance (Mann Whitney U test=-1.58 $p=0.11$). There were no

other significant differences between the groups in terms of other baseline socio-demographic characteristics.

[Insert table 1 here]

Predictors of treatment-resistance (TR)

Baseline clinical predictors of treatment resistance (TR) at five-year follow up for the whole sample and stratified by ethnicity and gender are presented in **Table 2**. Those patients who were defined as treatment resistant were more likely to have an early age of first contact with mental health services (<20 years) compared to the non-TR group (OR 2.49, 95% CI 1.25-4.94). There were significant interactions between age at first contact for psychosis with ethnicity ($p=0.02$) and gender ($p=0.002$). Therefore, in addition to exploring the impact of age at first contact in predicting TR in the cohort, we further stratified the analyses by gender and ethnicity. We observed that this relationship between an early age of first contact for psychosis (<20 year) and TR was significant in cases of Black ethnicity (OR 3.71, 95% CI 1.44-9.56) and in male patients (OR 3.13, 95% CI 1.35-7.23) (**Table 3**).

[Insert table 2 &3 here]

“Clozapine” group vs “met criteria” group

Among those patients who were defined as TR, 38 cases (46.9% of $N=81$, and 15.4% of 246 cases with a diagnosis of schizophrenia spectrum psychosis at study recruitment) commenced treatment with clozapine; whereas 43 cases (53.1% of $N=81$) met criteria for clozapine but did not commence it. A higher proportion of patients in the clozapine group (91%) lived with family members or friends compared to the “met criteria” group (48.0%) ($\chi^2=6.04$, $p=0.01$). The clozapine group exhibited more severe psychopathology ($t_{(27)}=2.49$, $p=0.02$) and negative symptoms (U test =2.410, $p=0.03$) compared to the “met criteria” group at first contact for psychosis (Supplementary Table 2).

The clozapine group had increased negative symptoms (mean 21.7 (SD=9.1) compared to the non-TR group (mean 15.4, SD=6.0) (U test=-2.22 $p=0.02$)

“Early-resistant” TR (E-TR) vs “late-resistant” TR (L-TR) and vs the non-TR groups

Among those with TR, 56 (70.0% of 80 with TR) were E-TR and 24 (30.0% of $N=80$) were L-TR. The E-TR group expressed more severe psychopathology at baseline (mean total PANSS score=69.9, SD=20.4) than the non-TR group (mean total PANSS score=60.9 SD=16.4) ($t_{(95)}=-1.98$, $p=0.05$) (Supplementary Table 3). Cases in the L-TR group were significantly younger at the time of first contact for psychosis (mean_{years} =23.7, SD=5.1) compared to the non-TR group (mean_{years}=27.9, SD=8.3) ($t_{(181)}=2.44$, $p=0.02$) (Supplementary Table 4).

A higher proportion of the E-TR group (74% of $n=56$) were male compared to the L-TR group (46%) ($\chi^2=6.39$, $p=0.01$). There were no other significant differences between the groups in terms of ethnicity, socio-demographic and clinical characteristics at baseline.

Discussion

This is the largest study of a first episode schizophrenia spectrum psychosis cohort to assess the clinical and demographic risk factors associated with the emergence of treatment resistance (TR). TR illness was seen in 34% of patients by five years follow-up. Our principal finding was that 70% of the treatment resistant cases did not respond to antipsychotics from illness onset.

An earlier age of first contact for psychosis was strongly associated with TR at five years follow up. This finding of an association between a first contact with mental health services for psychosis before the age of 20 and TR was most marked for males, and for those of black ethnicity. Early onset schizophrenia is associated with worse outcomes compared to adult onset schizophrenia (Ropcke and Eggers, 2005, Vyas *et al.*, 2007), and a younger age of illness onset has been previously associated with the emergence of treatment resistance

(Meltzer *et al.*, 1997, Vanelle, 1995), though our study is the first longitudinal study in first episode schizophrenia spectrum psychoses to identify this. These findings should alert clinicians to be more vigilant in individuals with a first episode of schizophrenia spectrum psychosis in late adolescence (age <20) in terms of their response (or lack thereof) to initial trials of antipsychotics and to be prepared to use clozapine more promptly when a lack of response is evident.

There was no difference between age of first contact in the TR group between males and females, though in the non-TR group, males were younger at the time of first contact. This observation, combined with the younger age of schizophrenia onset in those who eventually develop a treatment resistant course of illness is compatible with a greater role for neurodevelopmental impairment in this subgroup of schizophrenia patients, and a course of illness which differs premorbidly from that of non-TR patients. However, we did not find that the estimated deterioration in IQ scores, or a family history of psychosis was greater in the TR group compared to the non-TR group, and we did not identify that environmental risk factors were more prevalent in the non-TR group. These findings do not provide support for a neurodevelopmental pre-eminence in the TR group.

The severity of baseline clinical symptom profiles was not associated with TR over the course of the five year follow up. Although, we were unable to identify any associations with increased negative symptomatology at first contact and the emergence of TR, they were predictive of those who had been treated with clozapine. Further, we found that increased severity of psychotic symptoms at baseline was associated with E-TR compared to those with non-TR.

Early resistant and Late resistant TR (E-TR)

Of the TR group, 70% displayed unremitting symptoms from the time of first antipsychotic treatment. The finding that 23% of the total population met the criteria for TR from illness onset indicates that this course of illness is not associated with prior antipsychotic use and

raises the possibility that it may be a distinctive and homogenous schizophrenia subgroup, in line with evidence that there are biological differences between treatment resistant and treatment responsive schizophrenia (Demjaha *et al.*, 2014, Demjaha *et al.*, 2012). This finding mirrors the rate of 20% who displayed 'chronicity' from illness outset in a FEP population (Wiersma *et al.*, 1998), though is higher than a previous finding of 10% of FEP cases found to have shown no response to antipsychotics at the end of the first year of treatment (Robinson *et al.*, 1999). Further, our finding that 70% of the TR group displayed E-TR, is similar to an earlier study in established schizophrenia, which identified that over half of patients with 'poor outcomes', remained psychotic from illness onset (Kolakowska *et al.*, 1985). The high rates of early resistance of those with TR in this population is an important finding, which needs to be viewed in relation to the delay in clozapine use which exists in clinical practice (Howes *et al.*, 2012), specifically the under use of clozapine within the first 1-2 years of illness presentation.

A minority of those with TR (i.e. 30%) initially responded to antipsychotic medications, before developing L-TR. One possibility is that the loss of antipsychotic response may be due to the emergence of dopamine receptor supersensitivity in these cases. Dopamine supersensitivity is postulated to occur due to upregulation of dopamine receptors and neural adaptation (Chouinard, 1991, Iyo *et al.*, 2013) and it has been estimated that 50% of TR might be due to the emergence of dopamine supersensitivity (Chouinard and Chouinard, 2008). Conversely, previous studies have found that over the course of illness, approximately one in six develop a lack of antipsychotic response subsequent to relapses (Emsley *et al.*, 2012, Wiersma *et al.*, 1998), a lower rate of L-TR than the 30% identified in our study. It may be that there was a greater delay in treatment change for patients who relapsed in our naturalistic clinical setting, than in the closely monitored setting of the open label study of Emsley *et al.*, (Emsley *et al.*, 2012) in which patients had a treatment initiation at the time of relapse. This delay in antipsychotic use, may have contributed to the higher rate of L-TR which we have identified, due to the evolving nature of TR in the context of relapse.

Our findings indicate that two distinct patterns of TR develops in patients, with the majority displaying TR from the onset, and a smaller subset of patients developing TR after periods of relapse, or with a later emergence of an intrinsic TR with a propensity for poorer outcomes and attenuated antipsychotic response overtime.

Implications for practice

Increasingly, cases of first episode schizophrenia spectrum disorders in higher-income countries are managed within dedicated early intervention and first episode psychosis (FEP) services; however delays remain in the initiation of clozapine (Howes *et al.*, 2012). In our study, 70% of those with TR would have been most appropriately treated with clozapine at an early stage of their presentation, particularly given evidence that early treatment with clozapine is effective (Agid *et al.*, 2011), and that worse outcomes are seen with a delayed use of clozapine (Nielsen *et al.*, 2012a, Ucok *et al.*, 2015). There is a need for a greater awareness and appreciation within FEP services that early resistance to antipsychotics is a not uncommon phenomenon. We would conjecture that on the basis of our findings consideration for early and judicious use of clozapine is appropriate.

Access to clozapine

Clozapine was commenced in less than half of those with TR over the course of the 5 years follow up. Those who were commenced on clozapine in our study, were more likely to exhibit more severe psychotic symptoms, and increased negative symptomatology at baseline, when compared to those who 'met-criteria' for clozapine use, indicating that a more florid psychosis is likely a factor in a clinician's decision for the earlier use of clozapine in TR. Perhaps a more significant finding in relation to practice and clozapine initiation, was that those started on clozapine were significantly more likely to be living at home with family, compared to those who 'met criteria' for TR. Perhaps clozapine treatment is restricted for some who meet criteria for TR, due to a lack of family support (perceived or otherwise) or due to unstable living arrangements. These factors should prompt consideration for the

provision of more dedicated hospital and community facilities to allow for the successful completion of the early stages of clozapine use, with adequate supported accommodation provided as required, to enable continued clozapine use. There is some evidence that such an approach is effective in increasing access to clozapine (Beck *et al.*, 2014).

Methodological considerations

Strengths of this study include the quasi-prospective design which allowed for the follow up of first episode schizophrenia spectrum psychosis cases over the first five years of illness. We have examined the course of TR in a naturalistic setting, from the time of the first use of antipsychotic medication, describing the pattern of TR onset, and identifying robust associations with the onset of TR.

Limitations to our study design include the small population of female patients and the lack of a robust measure of medication adherence, which may have affected the association with meeting the criteria for TR (McCutcheon *et al.*, 2015). The unsystematic use of clozapine in this cohort is a further limitation in our estimation of TR, with over half of those meeting criteria for clozapine not treated with it.

We found notable clinical heterogeneity of course and outcome, with 34% of cases fulfilling the criteria for TR at 5 years, a relatively high rate, possibly reflecting the fact that a higher proportion were recruited from inpatient as opposed to community settings. A higher proportion recruited from inpatient settings, might indicate a greater clinical need, than those who were managed in the community setting (though who weren't recruited to this study). However, we did not identify a greater illness severity as measured by total PANSS scores in those recruited from an inpatient setting compared to those recruited from a community setting. Nonetheless, the increased proportion of cases that were inpatients at the time of recruitment, and the recruitment from clinical services rather than by population screening or other methods may mean that the rate of TRS identified is an overestimate. We were unable to directly assess neurodevelopmental risk factors, (excepting a lack of difference in IQ and

premorbid IQ between the TR and non TR groups), which one might postulate would be increased in those with a higher risk of TR relating to a younger age of onset.

Conclusions

The findings from this study indicate that an early contact for psychosis during the ages of 18-20, particularly in males is a strong predictor of TRS. Seventy percent of the TR subgroup presented with a treatment resistant picture at first contact, with no symptom remission occurring over the first six months of treatment. We did not find evidence suggesting that social factors and premorbid functioning were associated with the emergence of TR during the course of illness. Our findings reinforce the case for early assessment of treatment resistance in first episode patients so that clozapine may be considered and introduced promptly as a third line treatment in first episode schizophrenia. Future studies with larger samples are required to replicate and progress this important area of clinical prediction.

References

- Agid, O., Arenovich, T., Sajeev, G., Zipursky, R. B., Kapur, S., Foussias, G. & Remington, G.** (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. *Journal of Clinical Psychiatry* **72**, 1439-44.
- Andreasen, N. C., Carpenter, W. T., Jr., Kane, J. M., Lasser, R. A., Marder, S. R. & Weinberger, D. R.** (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. *American Journal of Psychiatry* **162**, 441-9.
- Beck, K., McCutcheon, R., Bloomfield, M. A., Gaughran, F., Reis Marques, T., MacCabe, J., Selvaraj, S., Taylor, D. & Howes, O. D.** (2014). The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach. *Acta Psychiatrica Scandinavica* **130**, 427-38.
- Carbon, M. & Correll, C. U.** (2014). Clinical predictors of therapeutic response to antipsychotics in schizophrenia. *Dialogues in clinical neuroscience* **16**, 505-24.
- Chouinard, G.** (1991). Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. *Schizophrenia Research* **5**, 21-33.
- Chouinard, G. & Chouinard, V. A.** (2008). Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. *Psychotherapy and Psychosomatics* **77**, 69-77.
- Demjaha, A., Egerton, A., Murray, R. M., Kapur, S., Howes, O. D., Stone, J. M. & McGuire, P. K.** (2014). Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. *Biological Psychiatry* **75**, e11-e13.
- Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S. & Howes, O. D.** (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. *American Journal of Psychiatry* **169**, 1203-10.
- Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S. A., Wiffen, B., Powell, J. & Murray, R. M.** (2009). High-potency cannabis and the risk of psychosis. *British Journal of Psychiatry* **195**, 488-491.
- Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., Dazzan, P., Mondelli, V., Paparelli, A., Kolliakou, A., Prata, D., Gaughran, F., David, A. S., Morgan, C., Sthal, D., Khondoker, M., MacCabe, J. H. & Murray, R. M.** (2013). Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users. *Schizophrenia Bulletin*.
- Emsley, R., Nuamah, I., Hough, D. & Gopal, S.** (2012). Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. *Schizophrenia Research* **138**, 29-34.
- Frank, J., Lang, M., Witt, S. H., Strohmaier, J., Rujescu, D., Cichon, S., Degenhardt, F., Nothen, M. M., Collier, D. A., Ripke, S., Naber, D. & Rietschel, M.** (2015). Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. *Molecular Psychiatry* **20**, 150-151.
- Heinze, G. & Schemper, M.** (2002). A solution to the problem of separation in logistic regression. *Statistics in Medicine* **21**, 2409-19.
- Howes, O. D., Vergunst, F., Gee, S., McGuire, P., Kapur, S. & Taylor, D.** (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. *British Journal of Psychiatry* **201**, 481-5.
- Iyo, M., Tadokoro, S., Kanahara, N., Hashimoto, T., Niitsu, T., Watanabe, H. & Hashimoto, K.** (2013). Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. *Journal of Clinical Psychopharmacology* **33**, 398-404.
- Kay, S. R., Fiszbein, A. & Opler, L. A.** (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* **13**, 261-76.

- Kolakowska, T., Williams, A. O., Ardern, M., Reveley, M. A., Jambor, K., Gelder, M. G. & Mandelbrote, B. M.** (1985). Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. *British Journal of Psychiatry* **146**, 229-39.
- Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W. & Davis, J. M.** (2014). Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method. *Schizophrenia Bulletin*.
- Lewis, S. W., Barnes, T. R., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H. & Jones, P. B.** (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. *Schizophrenia Bulletin* **32**, 715-23.
- Lin, C. C., Wang, Y. C., Chen, J. Y., Liou, Y. J., Bai, Y. M., Lai, I. C., Chen, T. T., Chiu, H. W. & Li, Y. C.** (2008). Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data. *Computer Methods and Programs in Biomedicine* **91**, 91-9.
- Malla, A., Norman, R., Schmitz, N., Manchanda, R., Bechard-Evans, L., Takhar, J. & Haricharan, R.** (2006). Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. *Psychological Medicine* **36**, 649-58.
- Mallett, R., Leff, J., Bhugra, D., Pang, D. & Zhao, J. H.** (2002). Social environment, ethnicity and schizophrenia. A case-control study. *Social Psychiatry and Psychiatric Epidemiology* **37**, 329-35.
- Martin, A. K. & Mowry, B.** (2016). Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia. *Psychological Medicine* **46**, 469-76.
- McCutcheon, R., Beck, K., Bloomfield, M. A., Marques, T. R., Rogdaki, M. & Howes, O. D.** (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. *Journal of Psychopharmacology* **29**, 892-7.
- McGuffin, P., Farmer, A. & Harvey, I.** (1991). A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. *Archives of General Psychiatry* **48**, 764-70.
- Meltzer, H. Y.** (1997). Treatment-resistant schizophrenia--the role of clozapine. *Current Medical Research and Opinion* **14**, 1-20.
- Meltzer, H. Y., Rabinowitz, J., Lee, M. A., Cola, P. A., Ranjan, R., Findling, R. L. & Thompson, P. A.** (1997). Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. *American Journal of Psychiatry* **154**, 475-82.
- Menezes, N. M., Arenovich, T. & Zipursky, R. B.** (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. *Psychological Medicine* **36**, 1349-1362.
- Morgan, C., Lappin, J., Heslin, M., Donoghue, K., Lomas, B., Reininghaus, U., Onyejiaka, A., Croudace, T., Jones, P. B., Murray, R. M., Fearon, P., Doody, G. A. & Dazzan, P.** (2014). Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. *Psychological Medicine* **44**, 2713-26.
- NICE.** (2014). *Psychosis and schizophrenia in adults: treatment and management (Clinical guideline 178)*. Royal College of Psychiatrists: London.
- Nielsen, J., Nielsen, R. E. & Correll, C. U.** (2012a). Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. *Journal of Clinical Psychopharmacology* **32**, 678-83.
- Nielsen, J., Roge, R., Schjerning, O., Sorensen, H. J. & Taylor, D.** (2012b). Geographical and temporal variations in clozapine prescription for schizophrenia. *European Neuropsychopharmacology* **22**, 818-24.
- Ortiz, B. B., Araujo Filho, G. M., Araripe Neto, A. G., Medeiros, D. & Bressan, R. A.** (2013). Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study. *Revista Brasileira de Psiquiatria* **35**, 432-4.
- Revier, C. J., Reininghaus, U., Dutta, R., Fearon, P., Murray, R. M., Doody, G. A., Croudace, T., Dazzan, P., Heslin, M., Onyejiaka, A., Kravariti, E., Lappin, J., Lomas, B., Kirkbride, J. B., Donoghue, K., Morgan, C. & Jones, P. B.** (2015). Ten-Year Outcomes of First-Episode Psychoses in the MRC AESOP-10 Study. *Journal of Nervous and Mental Disease* **203**, 379-86.

- Robinson, D. G., Woerner, M. G., Alvir, J. M., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R. & Lieberman, J. A.** (1999). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. *American Journal of Psychiatry* **156**, 544-9.
- Ropcke, B. & Eggers, C.** (2005). Early-onset schizophrenia: a 15-year follow-up. *European Child & Adolescent Psychiatry* **14**, 341-50.
- Sartorius, N., Gulbinat, W., Harrison, G., Laska, E. & Siegel, C.** (1996). Long-term follow-up of schizophrenia in 16 countries. A description of the International Study of Schizophrenia conducted by the World Health Organization. *Social Psychiatry and Psychiatric Epidemiology* **31**, 249-58.
- Schennach, R., Riedel, M., Musil, R. & Moller, H. J.** (2012). Treatment Response in First-episode Schizophrenia. *Clinical Psychopharmacology and Neuroscience* **10**, 78-87.
- Schneider, C., Papachristou, E., Wimberley, T., Gasse, C., Dima, D., MacCabe, J. H., Mortensen, P. B. & Frangou, S.** (2015). Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. *European Neuropsychopharmacology* **25**, 857-63.
- Singh, S. P., Cooper, J. E., Fisher, H. L., Tarrant, C. J., Lloyd, T., Banjo, J., Corfe, S. & Jones, P.** (2005). Determining the chronology and components of psychosis onset: The Nottingham Onset Schedule (NOS). *Schizophrenia Research* **80**, 117-30.
- Stroup, T. S., Gerhard, T., Crystal, S., Huang, C. & Olfson, M.** (2014). Geographic and clinical variation in clozapine use in the United States. *Psychiatric Services* **65**, 186-92.
- Stroup, T. S., Gerhard, T., Crystal, S., Huang, C. & Olfson, M.** (2016). Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. *American Journal of Psychiatry* **173**, 166-73.
- Ucok, A., Cikrikcili, U., Karabulut, S., Salaj, A., Ozturk, M., Tabak, O. & Durak, R.** (2015). Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. *International Clinical Psychopharmacology* **30**, 290-5.
- Vanelle, J. M.** (1995). [Treatment refractory schizophrenia]. *L'Encephale* **21 Spec No 3**, 13-21.
- Vanelle, J. M., Olie, J. P. & Levy-Soussan, P.** (1994). New antipsychotics in schizophrenia: the French experience. *Acta Psychiatrica Scandinavica Suppl* **380**, 59-63.
- Vyas, N. S., Hadjulic, M., Vourdas, A., Byrne, P. & Frangou, S.** (2007). The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. *European Child & Adolescent Psychiatry* **16**, 465-70.
- Wechsler, D.** (2001). *Wechsler Test of Adult Reading: WTAR*. Psychological Corporation.
- Wechsler D** (1997). *Wechsler adult intelligence scale*. The Psychological Corporation: San Antonio: TX.
- Wheeler, A., Humberstone, V. & Robinson, G.** (2009). Outcomes for schizophrenia patients with clozapine treatment: how good does it get? *Journal of Psychopharmacology* **23**, 957-965.
- WHO** (1992). *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines*. World Health Organization: Geneva.
- WHO** (1994). *Schedules for Clinical Assessment in Neuropsychiatry: Version 2 : Manual*. World Health Organization, Division of Mental Health.
- Wiersma, D., Nienhuis, F. J., Slooff, C. J. & Giel, R.** (1998). Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. *Schizophrenia Bulletin* **24**, 75-85.
- Wimberley, T., Støvring, H., Sørensen, H. J., Horsdal, H. T., MacCabe, J. H. & Gasse, C.** (2016). Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. *The Lancet Psychiatry*.

